Early Onset Pulmonary Events in Patients with Non-Small Lung Cancer or Other Cancers Taking Brigatinib or Other TKIs

Inclusion Criteria

• Provision to sign and date the consent form, indicating that he or she has been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating
• Stated willingness and ability to comply with all scheduled visits and study procedures, and be available for the duration of the study
• Be a male or female aged >= 18
• Must plan on starting brigatinib 90 mg QD or ‘other TKI’
• Suitable for treatment with brigatinib or ‘other TKI’ per either Food and Drug Administration (FDA) labels, an acceptable clinical indication or within a clinical trial
• Participants must plan on taking brigatinib or ‘other TKI’ as the only systemic cancer treatment. This means that participants cannot be receiving other targeted therapies, chemotherapies, or immunotherapies while on said TKI (Exceptions: non-immunosuppressive supportive cancer therapies such as bone targeting agents [e.g., denosumab], and anti-emetics are allowed)
• Must have hemoglobin (Hb) of >= 10 g/dL
• Recovered from clinically relevant toxicities (in the opinion of the investigator) related to prior anticancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, version [v]4.03) grade =< 2
• Have Eastern Cooperative Oncology Group (ECOG) performance status =< 2
• Must have clearly documented information of previously received systemic cancer treatments including chemotherapy, immunotherapy, small molecule tyrosine-kinase inhibitors (incl. ALK-targeted TKI) and stop date of most recent systemic therapy

Exclusion Criteria

• Have baseline oxygen supplementation requirement (i.e., resting oxygen [O2] saturation [sats] on room air < 90%)
• Have history or presence of pulmonary interstitial disease or drug-related pneumonitis on CT imaging of chest performed within 28 days prior to starting brigatinib or ‘other TKI’
• Have malabsorption syndrome or other gastrointestinal (GI) illness that could affect oral absorption of brigatinib or ‘other TKI’ in the opinion of the investigator
• Have had a blood transfusion within past 120 days
• Have received any small molecule inhibitors, including crizotinib, within 7 days of the first dose of brigatinib (e.g., If first scheduled dose of brigatinib is on a Monday, May 1st, 2017 then last dose of the prior line of small molecule inhibitor must have been given BEFORE Monday, April 24, 2017)
• Have received cytotoxic chemotherapy, investigational agents, or cytotoxic doses of radiation to lung tissue within 14 days prior to starting brigatinib or ‘other TKI’
• Have received immunotherapy within 28 days of first dose of brigatinib or ‘other TKI’
• Be on corticosteroid within 48 hours prior to first dose of brigatinib or ‘other TKI’
• Per the study investigator, study candidate has uncontrolled, or active cardiac, pulmonary or hematologic disease that can affect interpretation of DLCO, specifically including, but not restricted to: * Pulmonary interstitial disease or drug-related pneumonitis * Symptomatic/poorly-controlled congestive heart failure (CHF) within 6 months prior to first dose * Symptomatic/poorly-controlled pulmonary embolism within last 6 months
• Have an ongoing or active infection. The requirement for intravenous (IV) antibiotics is considered active infection
• Have a known or suspected hypersensitivity to brigatinib (AP26113) or its excipients
• Have any condition or illness that, in the opinion of the investigator, would compromise participant safety or interfere with evaluation of the drug study